http://www.wearecentralpa.com/news/new-cancer-drug-for-dogs/635311559 ;
<http://www.wearecentralpa.com/news/new-cancer-drug-for-dogs/635311559>
The U.S. Food and Drug Administration announced Tuesday that it's given
conditional approval for the first new animal drug to treat canine lymphoma.
Also called lymphosarcoma, lymphoma is a type of cancer in dogs. The FDA said
the active ingredient in Tanovea-CA1 is rabacfosadine, a substance that kills
rapidly growing cancer cells.
Lymphoma can affect virtually any organ in the body, but it most commonly
starts in organs that function as part of the immune system, such as the lymph
nodes, spleen, and bone marrow. The signs of lymphoma in dogs vary depending on
which organs are affected.
Tanovea-CA1 must be prescribed by a licensed veterinarian because professional
expertise is needed to correctly diagnose lymphoma in dogs, determine the best
treatment, and manage potential side effects. Tanovea-CA1, which comes in a
concentrated form, is diluted and given into a vein over 30 minutes. The
infusion should be given by or under the supervision of a veterinarian
experienced in chemotherapy.
The "CA1" in Tanovea-CA1 means the drug is conditionally approved. Only animal
drugs intended for minor species, such as ferrets or fish, or for minor uses in
a major species, such as to treat certain types of cancer in dogs, are eligible
for conditional approval. Tanovea-CA1's conditional approval means that when
used according to the label, the drug is safe and has a "reasonable expectation
of effectiveness" for treating lymphoma in dogs.
